RESUMO
Tumor necrosis factor (TNF) is a proinflammatory cytokine implicated in pathogenesis of multiple autoimmune and inflammatory diseases. Anti-TNF therapy has revolutionized the therapeutic paradigms of autoimmune diseases and became one of the most successful examples of the clinical use of monoclonal antibodies. Currently, anti-TNF therapy is used by millions of patients worldwide. At the moment, fully human anti-TNF antibody Adalimumab is the best-selling anti-cytokine drug in the world. Here, we present a story about a highly potent anti-TNF monoclonal antibody initially characterized more than 20 years ago and further developed into chimeric and humanized versions. We present comparative analysis of this antibody with Infliximab and Adalimumab.
Assuntos
Adalimumab/biossíntese , Anticorpos Monoclonais Humanizados/biossíntese , Anticorpos Monoclonais/biossíntese , Artrite Reumatoide/tratamento farmacológico , Infliximab/biossíntese , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adalimumab/isolamento & purificação , Adalimumab/farmacologia , Animais , Anti-Inflamatórios não Esteroides , Anticorpos Monoclonais/história , Anticorpos Monoclonais/isolamento & purificação , Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais Humanizados/história , Anticorpos Monoclonais Humanizados/isolamento & purificação , Anticorpos Monoclonais Humanizados/farmacologia , Artrite Reumatoide/genética , Artrite Reumatoide/imunologia , Artrite Reumatoide/patologia , Clonagem Molecular , Expressão Gênica , História do Século XX , História do Século XXI , Humanos , Infliximab/isolamento & purificação , Infliximab/farmacologia , Camundongos , Psoríase/tratamento farmacológico , Psoríase/genética , Psoríase/imunologia , Psoríase/patologia , Espondilite Anquilosante/tratamento farmacológico , Espondilite Anquilosante/genética , Espondilite Anquilosante/imunologia , Espondilite Anquilosante/patologia , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/imunologiaRESUMO
This study examined the ability of the recombinant human interleukin 1 receptor antagonist (IL-1ra) to block interleukin 1 (IL-1)-mediated experimental metastases from the A375M human melanoma. In vivo, IL-1ra administrated at concentrations > or = 200 times IL-1 significantly inhibited the increase in lung colonies induced by IL-1 in nude mice. The response to IL-1 was significantly inhibited when IL-1ra was administered simultaneously with or 1 to 3 h before IL-1. In vitro, the incubation of IL-1-activated endothelial cells with IL-1ra prevented the increase in adhesion of A375M melanoma cells. At the same experimental conditions, IL-1ra inhibited the augmented expression of the intracellular and vascular cell adhesion molecules 1 and E-selectin induced by IL-1 on endothelial cells. Lipopolysaccharide, an IL-1 inducer, increased the number of lung colonies in nude mice. IL-1ra injected with or 1 h after lipopolysaccharide inhibited this augmentation, suggesting a role for host-produced IL-1 in metastasis formation.
Assuntos
Anticarcinógenos/uso terapêutico , Interleucina-1/toxicidade , Lipopolissacarídeos/toxicidade , Neoplasias Pulmonares/prevenção & controle , Neoplasias Pulmonares/secundário , Melanoma/patologia , Metástase Neoplásica/prevenção & controle , Sialoglicoproteínas/uso terapêutico , Animais , Linhagem Celular , Feminino , Humanos , Proteína Antagonista do Receptor de Interleucina 1 , Camundongos , Camundongos Nus , Proteínas Recombinantes/uso terapêutico , Proteínas Recombinantes/toxicidade , Transplante Heterólogo , Células Tumorais CultivadasRESUMO
We have studied the cytokine regulation of cell surface and soluble intercellular adhesion molecule 1 (ICAM-1) expression on the human melanoma cell line A375M. Unstimulated cells express ICAM-1 on their cell surface but do not secrete significant levels of soluble ICAM-1. Interleukin 1, interleukin 6, tumor necrosis factor, and gamma-interferon all increased cell surface expression of ICAM-1. Tumor necrosis factor, interleukin 1, and gamma-interferon also caused the release of soluble ICAM-1. The serum of melanoma patients has been reported to contain elevated levels of soluble ICAM-1; however, the source of this ICAM-1 is unclear. The serum from nude mice bearing s.c. human melanoma tumors was found to contain soluble human ICAM-1. ICAM-1 levels showed a positive correlation with tumor weight. The release of ICAM-1 from melanoma tumors, in response to host-derived cytokines, may have relevance to immune recognition of the tumor.
Assuntos
Moléculas de Adesão Celular/metabolismo , Melanoma/metabolismo , Animais , Moléculas de Adesão Celular/sangue , Humanos , Molécula 1 de Adesão Intercelular , Interferon gama/farmacologia , Interleucina-1/farmacologia , Interleucina-6/farmacologia , Melanoma/sangue , Camundongos , Camundongos Nus , Células Tumorais CultivadasRESUMO
We have previously reported that treatment with interleukin 1 (IL-1) induced the augmentation of lung tumor colonies by a human melanoma in nude mice. Here we have investigated the involvement of the alpha 4 beta 1 integrin, the very late antigen 4 (VLA-4) in this augmentation. A375M melanoma cells expressed high levels of VLA-4 and preferentially adhered to a surface coated with vascular cell adhesion molecule 1 (VCAM-1), the ligand for VLA-4 on activated endothelial cells. This adhesion was inhibited by treating tumor cells with saturating concentrations of mAb to VLA-4. The production of lung colonies was significantly enhanced in nude mice given an injection of IL-1 before A375M melanoma cells. Immunoperoxidase staining showed that VCAM-1 could be expressed on lung vascular endothelium of mice in response to IL-1. Pretreatment of melanoma cells with a mAb to VLA-4 completely abrogated the IL-1-induced augmentation of lung colonies. Using two metastatic melanoma clones (clones 2/4 and 2/60) that expressed different levels of VLA-4, we found that only VLA-4-bearing cells adhered to a VCAM-1-coated surface and formed enhanced numbers of lung colonies in IL-1-treated nude mice. This augmentation was inhibited by pretreating the tumor cells with anti-VLA-4 mAb. These results demonstrate, in vivo, the functional involvement of VLA-4 on melanoma cells in IL-1-mediated lung colony augmentation, most probably involving the interaction of tumor cells with VCAM-1 on activated endothelial cells.
Assuntos
Moléculas de Adesão Celular/metabolismo , Interleucina-1/farmacologia , Neoplasias Pulmonares/secundário , Melanoma/secundário , Receptores de Antígeno muito Tardio/fisiologia , Animais , Anticorpos Monoclonais/farmacologia , Adesão Celular/efeitos dos fármacos , Endotélio Vascular/metabolismo , Feminino , Humanos , Neoplasias Pulmonares/irrigação sanguínea , Melanoma/metabolismo , Camundongos , Camundongos Nus , Receptores de Antígeno muito Tardio/antagonistas & inibidores , Receptores de Antígeno muito Tardio/metabolismo , Células Tumorais Cultivadas , Molécula 1 de Adesão de Célula VascularRESUMO
We recently developed a method for the isolation and purification of tumour-derived endothelium. In this study the phenotypic and functional properties of human tumour-derived microvascular endothelial cells (TdMEC) were examined. Endothelium obtained from human adrenal gland specimens (HAMEC) was used as a reference microvascular endothelial cell population. TdMEC formed a confluent monolayer with the typical morphological appearance of endothelium and were positive for endothelial markers such as Ulex-1 lectin, CD31 antigen, von Willebrand Factor and VE-cadherin. The addition of acidic Fibroblast Growth Factor (aFGF), basic FGF (bFGF) or Vascular Endothelial Growth Factor (VEGF) substantially improved proliferation of TdMEC; and kidney carcinoma derived endothelial cells were more responsive to FGFs, whereas glioblastoma derived endothelial cells greatly responded to VEGF TdMEC expressed high levels of the VEGF receptors, KDR/flk-1 and Flt-1, as shown by northern blot analysis. TdMEC expressed the adhesion molecules ICAM-1, VCAM-1 and E-selectin that could be further increased by exposing TdMEC culture to interleukin-1. All the TdMEC expressed interleukin-8 mRNA. These findings show that TdMEC in vitro maintain several of the features described for microvasculature. Thus, TdMEC represent a useful tool to study markers for tumor vasculature.
Assuntos
Endotélio Vascular/citologia , Endotélio Vascular/fisiologia , Neoplasias/irrigação sanguínea , Lectinas de Plantas , Antígenos CD , Caderinas/biossíntese , Moléculas de Adesão Celular/biossíntese , Divisão Celular/efeitos dos fármacos , Fatores de Crescimento Endotelial/farmacologia , Endotélio Vascular/metabolismo , Fator 1 de Crescimento de Fibroblastos/farmacologia , Fator 2 de Crescimento de Fibroblastos/farmacologia , Humanos , Interleucina-8/biossíntese , Lectinas/biossíntese , Linfocinas/farmacologia , Microcirculação , Mitógenos/farmacologia , Fenótipo , Molécula-1 de Adesão Celular Endotelial a Plaquetas/biossíntese , Fator de Crescimento Derivado de Plaquetas/farmacologia , Proteínas Proto-Oncogênicas/biossíntese , Receptores Proteína Tirosina Quinases/biossíntese , Receptores de Fatores de Crescimento/biossíntese , Receptores de Fatores de Crescimento do Endotélio Vascular , Células Tumorais Cultivadas , Fator A de Crescimento do Endotélio Vascular , Receptor 1 de Fatores de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio Vascular , Fator de von Willebrand/biossínteseRESUMO
We have demonstrated that patients with ovarian carcinoma have higher levels of soluble intercellular adhesion molecule-1 (ICAM-1) in their serum and ascitic fluids than serum from normal individuals and non-neoplastic gynaecological disease or ascites from patients with cirrhosis. In order to investigate the source of the ICAM-1, and to study the mechanisms which regulate ICAM-1 release in ovarian carcinoma, we have employed the nude mouse model system. Three different human ovarian carcinoma (HOC) cell lines were grown as ascitic tumours in the peritoneal cavity of nude mice. HOC xenografts harvested from nude mice expressed comparable levels of ICAM-1 on their cell surface. Human ICAM-1 was detected, with a species-specific ELISA, in serum and ascitic fluid of tumour-bearing mice, confirming that the tumours were the source of the ICAM-1. The three HOC xenografts showed different levels of ICAM-1 release, but within each xenograft model the level of ICAM-1 in serum and ascitic fluid correlated with the tumour burden. The level of ICAM-1 released by the HOC xenografts could be increased by in vivo treatment with interferon gamma (IFN-gamma). Interleukin 1 (IL-1), tumour necrosis factor (TNF) and IFN gamma increased the cell surface expression of ICAM-1 and caused the release of soluble ICAM-1 from HOC cells established in vitro. The nude mouse provides a useful system in which to study the effects of modulating ICAM-1 release on the progression of ovarian carcinoma and suggests that measuring ICAM-1 levels in the blood or ascites of patients may provide an indication of tumour burden.
Assuntos
Líquido Ascítico/metabolismo , Molécula 1 de Adesão Intercelular/metabolismo , Neoplasias Ovarianas/metabolismo , Animais , Feminino , Humanos , Molécula 1 de Adesão Intercelular/sangue , Interferon gama/farmacologia , Camundongos , Camundongos Nus , Transplante de Neoplasias , Neoplasias Ovarianas/sangue , Solubilidade , Transplante Heterólogo , Células Tumorais CultivadasRESUMO
The growth and metastatic behavior of human tumor cell lines were studied in nude, beige/nude/xid (bg/nu/xid) and severe combined immunodeficient (SCID) mice. One melanoma, two colon carcinomas and one renal carcinoma grew subcutaneously in the three strains of mice with no significant differences in tumor take and growth rate. One ovarian carcinoma formed a subcutaneously growing tumor only in SCID mice. Spontaneous metastases were observed only in mice with advanced subcutaneous tumors or at histological examination, but more frequently in bg/nu/xid and SCID mice than in nude mice. A375M melanoma formed more lung colonies in nude and bg/nu/xid mice than in SCID mice. HT-29LM colon carcinoma injected intravenously or intrasplenically formed more lung and liver colonies and lymph node metastases in bg/nu/xid mice than in nude and SCID mice. The treatment of SCID mice with anti-asGM1 serum depleted NK activity and enhanced the number of lung colonies by A375M melanoma and HT-29LM colon carcinoma. Bg/nu/xid or SCID mice may therefore offer some advantages for studying the malignant behavior of human solid tumors and differences may depend on the experimental conditions and on the tumor type.
Assuntos
Carcinoma/patologia , Neoplasias do Colo/patologia , Neoplasias Renais/patologia , Melanoma/patologia , Metástase Neoplásica , Neoplasias Ovarianas/patologia , Animais , Feminino , Humanos , Camundongos , Camundongos Endogâmicos , Camundongos Nus , Camundongos SCID , Transplante de Neoplasias , Neoplasias ExperimentaisRESUMO
The synthetic matrix metalloproteinase inhibitor batimastat was tested for its ability to inhibit growth and metastatic spread of the B16-BL6 murine melanoma in syngeneic C57BL/6N mice. Intraperitoneal administration of batimastat resulted in a significant inhibition in the number of lung colonies produced by B16-BL6 cells injected i.v. The effect of batimastat on spontaneous metastases was examined in mice inoculated in the hind footpad with B16-BL6 melanoma. The primary tumor was removed surgically after 26-28 days. Batimastat was administered twice a day from day 14 to day 28 (pre-surgery) or from day 26 to day 44 (post-surgery). With both protocols, the median number of lung metastases was not significantly affected, but there was a significant reduction in the weight of the metastases. Finally, the effect of batimastat was examined on s.c. growth of B16-BL6 melanoma. Batimastat administered daily, starting at day of tumor transplantation, resulted in a significant growth delay, whereas treatment starting at advanced stage tumor only reduced tumor growth marginally. Our results indicate that a matrix metalloproteinase inhibitor can not only prevent the colonization of secondary organs by B16-BL6 cells but also limit the growth of solid tumors.
Assuntos
Melanoma Experimental/tratamento farmacológico , Melanoma Experimental/enzimologia , Metaloendopeptidases/antagonistas & inibidores , Fenilalanina/análogos & derivados , Tiofenos/farmacologia , Animais , Divisão Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Feminino , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/secundário , Melanoma Experimental/secundário , Camundongos , Camundongos Endogâmicos C57BL , Transplante de Neoplasias , Fenilalanina/sangue , Fenilalanina/farmacocinética , Fenilalanina/farmacologia , Tiofenos/sangue , Tiofenos/farmacocinética , Distribuição TecidualRESUMO
The interleukin-1alpha(IL-1) gene was introduced by retroviral gene transfer into the A375P human melanoma cell line. Two hygromycin-resistant colonies, colony 3 and colony 6, which respectively do not and do express and release IL-1, were selected on the basis of Northern blot and ELISA. Both colonies adhered to resting human endothelial cells (EC) to the same extent. Pre-treatment of EC for 6 hr with conditioned medium (CM) from colony 6, but not from colony 3, increased the adhesion of A375P melanoma and HT-29 colon-carcinoma cells to EC. This increase was blocked by adding interleukin-l-receptor antagonist (IL-1ra) to the EC monolayer. Treatment of EC with colony-6-CM increased the expression of intercellular-adhesion molecule I (ICAM-1), vascular-cell-adhesion molecule I (VCAM-1) and E-selectin. Co-cultivation of colony-6 but not colony-3 melanoma cells with EC caused time-dependent increased expression of these adhesion proteins, reflecting their kinetics of expression on EC. Treating the EC with monoclonal antibodies to VCAM-1 and E-selectin abolished the colony-6-CM-induced increase in adhesion respectively to A375P melanoma and HT-29 colon-carcinoma cells. In vivo, i.v. injection of colony-6 cells in nude mice increased the expression of VCAM-1 on lung microvascular EC. The retention of radiolabeled A375P melanoma cells in the lung was increased in nude mice primed with colony-6 cells, but not with colony-3 cells, injected 6 hr earlier. These results demonstrate that IL-1 produced constitutively by transformed A375P melanoma cells is functionally active, inducing adhesion molecules on EC that enhance their adhesiveness for tumor cells and increase tumor-cell retention in the lung of nude mice.
Assuntos
Interleucina-1/genética , Pulmão/patologia , Melanoma/genética , Animais , Adesão Celular/genética , Moléculas de Adesão Celular/metabolismo , Selectina E/metabolismo , Endotélio/patologia , Feminino , Humanos , Molécula 1 de Adesão Intercelular/metabolismo , Interleucina-1/metabolismo , Melanoma/metabolismo , Melanoma/patologia , Camundongos , Camundongos Nus , Transfecção , Células Tumorais Cultivadas , Molécula 1 de Adesão de Célula Vascular/metabolismoRESUMO
All trans-retinoic acid (ATRA) induces complete remission in acute-promyelocytic-leukemia (APL) patients. This study investigated the adhesive properties of APL cells for the endothelium and the extracellular matrix, their motility and the effect of ATRA on these functions. Blasts from 7 APL patients adhered to resting and IL-1-activated endothelium, to the same degree as normal PMN. Adhesion was partially mediated by ICAM-1 and, for IL-1-activated endothelium, by VCAM-1 and E-selectin. These cells showed less adhesiveness for the matrix than PMN, although they maintained the same substrate preference: they adhered to fibronectin and thrombospondin, but not to laminin and type-IV collagen. Exposure to ATRA in vitro (1 microM for 48 to 96 hr) increased the adhesiveness of APL cells; this effect was particularly evident in the case of sub-endothelial matrix and fibronectin. A similar increment in adhesiveness was observed when comparing cells from 2 patients before and after treatment with ATRA. APL cells migrated in response to fMLP and motility was increased by ATRA. In conclusion, APL cells were less adhesive to the matrix than PMN, but treatment with ATRA considerably enhanced their adhesive properties. This could be important in determining the efflux of leukemic cells from the bone marrow and their tissue infiltration during ATRA therapy.
Assuntos
Antineoplásicos/farmacologia , Adesão Celular/efeitos dos fármacos , Movimento Celular/efeitos dos fármacos , Leucemia Promielocítica Aguda/fisiopatologia , Tretinoína/farmacologia , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Selectina E/fisiologia , Endotélio/fisiopatologia , Matriz Extracelular , Feminino , Humanos , Molécula 1 de Adesão Intercelular/fisiologia , Leucemia Promielocítica Aguda/metabolismo , Leucemia Promielocítica Aguda/patologia , Masculino , Pessoa de Meia-IdadeRESUMO
Human immunodeficiency virus-1 (HIV-1)-Tat, the transactivating gene product of HIV-1, has been shown to interact with different cell types, inducing gene expression, altering their growth and migratory behavior. In this study we examined whether Tat might affect functions of acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin's lymphoma (NHL), relevant to the in vivo dissemination. Our results show that Tat significantly augmented the motility of the two AIDS-related Burkitt's lymphoma cell lines (AS283 and PA682PB) and AIDS-primary effusion lymphoma cell line (HBL-6-AIDS-PEL). Mutations in RGD or basic domain of Tat (KGE-MBP and LxI-MBP, respectively) sharply reduced migration compared with wild type, suggesting that both domains are required for migration. In contrast, a Tat protein mutation outside the active domains (NH(2)-TAT-GST) did not reduce lymphoma cell migration. The treatment of lymphoma cells with Tat did not influence their adhesion to matrix proteins or to human vascular endothelial cells, but endothelial cells treated with Tat became more adhesive to lymphoma cells. Flow cytometric analysis showed that treatment of endothelial cells with Tat induced the cell surface expression of the adhesion molecules vascular cell adhesion molecule-1 (VCAM-1) and E-selectin and increased the expression of intercellular adhesion molecule-1 (ICAM-1). Only antibodies against VCAM-1 on endothelial cells or against the VLA-4 integrin expressed on AS283 cells inhibited the increment of adhesion, indicating the relevance of this pathway in the adhesion of lymphoma cells to vascular endothelium. In our work, we show for the first time that Tat can enhance the migration of lymphoma cells and their adhesion to endothelial cells, two processes that may contribute to the malignant behavior of NHL in patients with AIDS.